Bio-Path (NASDAQ:BPTH) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock.

Separately, Roth Mkm raised their price objective on Bio-Path from $12.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, March 27th.

Bio-Path Trading Up 5.9 %

Bio-Path stock opened at $3.23 on Tuesday. Bio-Path has a twelve month low of $2.70 and a twelve month high of $44.80. The stock has a 50 day moving average of $5.59 and a two-hundred day moving average of $8.56. The stock has a market capitalization of $2.20 million, a price-to-earnings ratio of -0.08 and a beta of 0.35.

Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings data on Friday, March 8th. The company reported ($5.40) earnings per share for the quarter, hitting analysts’ consensus estimates of ($5.40). During the same period last year, the firm earned ($10.60) EPS. Equities analysts predict that Bio-Path will post -18.71 earnings per share for the current year.

Hedge Funds Weigh In On Bio-Path

Several hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new position in Bio-Path in the first quarter valued at $38,000. Citadel Advisors LLC purchased a new stake in shares of Bio-Path during the third quarter worth about $35,000. Renaissance Technologies LLC bought a new stake in Bio-Path in the second quarter valued at about $70,000. Vanguard Group Inc. increased its holdings in Bio-Path by 77.5% in the fourth quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock valued at $125,000 after buying an additional 117,914 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in Bio-Path in the third quarter valued at about $77,000. Hedge funds and other institutional investors own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.